Business
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call Canada Ne...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\n Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n MISSISSAUGA, ON\n \n\n ,\n \n\n Aug. 1, 2024\n \n\n /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (\"\n \n Cipher\n \n \" or the \"\n \n Company\n \n \") today announced that it will release its financial results for the second quarter of 2024 after the market close on\n \n Thursday, August 8, 2024\n \n . The Company will also hold a conference call on\n \n Friday, August 9, 2024\n \n at\n \n 8:30AM ET\n \n to discuss the results and corporate developments.\n \n\n\n CONFERENCE CALL DETAILS\n \n\n\n\n\n\n\n\n DATE:\n \n\n\n\n\n\n August 9, 2024\n \n\n\n\n\n\n\n\n TIME:\n \n\n\n\n\n\n 8:30AM\n \n\n\n\n\n\n\n\n DIAL-IN NUMBER:\n \n\n\n\n\n\n (+1) 437-900-0527 or 888-510-2154\n \n\n\n\n\n\n\n\n REPLAY:\n \n\n\n\n\n\n (+1) 289-819-1450 or 888-660-6345 Code: 28622#\n \n\n\n\n\n\n\n\n\n\n\n Expires: August 16, 2024\n \n\n\n\n\n\n\n\n WEBCAST:\n \n\n\n\n\n\n\n https://app.webinar.net/0Lpez7dn8v4\n \n\n\n\n\n\n\n\n\n\n About Cipher Pharmaceuticals Inc.\n \n\n\n\n Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit\n \n\n www.cipherpharma.com\n \n\n .\n \n\n SOURCE Cipher Pharmaceuticals Inc.\n \n\n\n\n\n\n View original content:\n \n http://www.newswire.ca/en/releases/archive/August2024/01/c9842.html\n \n\n\n\n\n","length":54...